TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06562894: A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SYHX1901 Tablets in the Treatment of Severe Alopecia Areata

Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd. · Phase: PHASE2 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 156 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,256,000

Rescue Site Savings

+$5,443,800

Unlock Full NCT06562894 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06562894 Rescue Dossier →